Vascular Patches Market is estimated to be valued at USD 443.6 Mn in 2025 and is expected to reach USD 755.3 Mn in 2032, exhibiting a compound annual growth rate (CAGR) of 7.9% from 2025 to 2032.
The Vascular Patches Market is driven by the rising prevalence of cardiovascular diseases and the increasing number of vascular surgeries worldwide. Advancements in natural biomaterials, such as bioengineered and synthetic patches offering enhanced biocompatibility, further support market growth. For instance, companies like Baxter and LeMaitre Vascular have introduced innovative patch designs that reduce post-operative complications. Additionally, aging populations and growing healthcare investments globally are fueling the demand for vascular repair solutions.
|
Event |
Description and Impact |
|
Regulatory Policy Shifts in Key Markets |
|
|
Geopolitical Trade Tensions |
|
|
Technological Advancements in Patch Design |
|
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
The vascular-patch arena blends already-sold items with hopeful newcomers still in lab testing. For example, Hancock Ja-fee Labs VasoRing and Vivex Biomedicals VasCure are early-stage projects meant to speed vessel repair and cut down on scarring. At the same time, several patches have cleared regulators and are on hospital shelves.
CryoLifes PerClot, approved as a hemostatic spray, is also used as a sealing layer in some grafts. Surgeons routinely reach for Edwards Pericardial Patch, LeMaitre Vasculars ProCol and Xenosure, or Admeduss CardioCel thanks to their strength and compatibility with human tissue.
Terumo Aortics Vascutek patch gives doctors a durable synthetic choice, while CryoLifes ArteGraft and Neovascs PeriPatch lean on animal tissue.
Together, these products support a wide range of procedures, from carotid endarterectomy through AV access to fixes for peripheral arteries.
The pipeline thus walks a tight line, balancing fresh bioengineering ideas and the proven reliability of existing synthetic and biologic options. With ongoing research and smart partnerships, the field looks set to widen its toolbox and lift patient results in vascular surgery.
Patent activity in the vascular patch arena keeps climbing, showing that firms are pushing fresh ideas in biomaterials, design, and surgical use. Inventors are zeroing in on anti-calcification coatings, stronger composite blends, and fully bioresorbable layers that promise better healing and tissue fit. Heavyweights such as LeMaitre Vascular, Becton Dickinson, Terumo Aortic, Baxter International, and W. L. Gore together file most of the worlds patents.
By locking up new claims, these players shore up market share and keep their R&D pipelines flowing. Recent grants include: - US11878945B1, which protects a two-layer patch built for extra strength and seamless tissue handover. - EP4056763A1, covering a bovine-pericardium sheet treated with enzymes to curb calcification and swelling.
New filings also spotlight nanofiber mats, 3D printing, and self-repair materials that push patches toward the next generation. Such tools promise faster healing, less immune response, and the flexibility surgeons crave in varied procedures. Taken together, the dense patent landscape points to innovation as the growth engine for the vascular patch sector going forward.
Around the world, how much hospitals get paid for vascular patches can change a lot, mainly because each region has its own payment rules and coding practices. Important billing codes to know are ICD-10 entries-say, I70.0 for artery hardening-CPT numbers like 35121 for carotid bypass-HCPCS code C1768 for the patch itself plus the DRG groups tied to big heart procedures. In the United States, Medicare chips in roughly 80% of the approved bill once the deductible is met, while most private plans cover another 70% to 90%. Back in 2020, Medicare outlayed about $2.5 billion covering 65% of the patch costs, and private carriers added roughly $4.2 billion, already settling around 80%.
Across the European Union, national health services usually shoulder close to 85% of the charge, and supplemental policies make up the last 15% to 30%. Public budgets in the EU picked up about 1.8 billion and private plans around 800 million for patches and alike. Japan follows the same broad model: the National Health Insurance covers roughly 70% while patients settle the remaining 30%. Many people carry private policies that replace 70% to 90% of the out-of-pocket share, leading to 120 billion yen in NHI spending and about 50 billion yen from the private pool. Taken together, these patch payment patterns heavily influence how quickly new devices reach operating rooms and patients everywhere.
Vascular patches are vital when doctors treat peripheral artery disease (PAD), repair abdominal aortic aneurysms (AAA), or open narrowed carotid arteries in carotid artery stenosis (CAS). Being clear about what prescribers prefer allows device makers to update products and education so tools fit real-world procedures. In early-stage PAD physicians first recommend exercise and drugs, typically an antiplatelet such as aspirin or clopidogrel along with a statin. Once the disease worsens, during many endovascular jobs they reach for bovine pericardium patches like Vascu-Guard or the classic PTFE brand Gore-Tex.
When PAD is advanced, surgeons perform a bypass using the patient’s own vein or a synthetic graft and often seat a patch of bovine pericardium, PTFE, or even a human umbilical vein graft such as the Dardik Biograft. Abdominal aortic aneurysms follow a different plan: small lesions get watchful waiting with tight blood-pressure control and statins.
Large or fast-growing AAAs, however, call for endovascular stent-graft repair, while the open route uses Dacron fabric strengthened by a vascular patch. Carotid artery stenosis management starts similarly for low-risk visitors, relying on antiplatelets and statins alone. When a patient shows symptoms, a carotid endarterectomy is done and the gap sealed with patches of bovine pericardium, PTFE, or Hemashield Dacron. For high-risk cases, doctors may pick carotid artery stenting followed by dual antiplatelet therapy instead. Throughout all these choices, surgeons always prioritize patch materials that guarantee strength, durability, and low rates of restenosis.
Synthetic vascular patches are expected to lead the market share of 63.8% in 2025, largely due to a wave of new product launches that promise better durability and ease of use during surgical procedures. These patches, often made of materials like ePTFE or Dacron, are increasingly preferred in vascular surgeries where consistency and lower infection risk matter. Major players like LeMaitre and Getinge are consistently expanding their synthetic product lines to meet surgeon demand for reliable, off-the-shelf solutions.
Carotid endarterectomy is projected to dominate the application segment by 2025, driven by a steady rise in cardiovascular conditions such as carotid artery disease. This minimally invasive procedure benefits greatly from vascular patches that ensure vessel integrity after plaque removal. With heart disease remaining the world’s leading cause of death, especially in aging populations, more patients are undergoing endarterectomies—cementing this category's top place in vascular patch demand.
Hospitals and clinics are poised to capture the bulk of vascular patch usage by 2025, as they remain the first stop for urgent and complex cardiovascular interventions. Their access to surgical teams, imaging tools, and post-op care creates an ideal setting for procedures requiring vascular repair. Moreover, with increased investment in hospital infrastructure worldwide, these facilities are better equipped than ever to handle high volumes of patch-related surgeries.
To learn more about this report, Download Free Sample
North America is expected to lead the global vascular patches market with a projected 33.50% share in 2025, driven by a high burden of cardiovascular diseases and strong healthcare infrastructure. The region’s dominance is bolstered by a rising number of vascular surgeries and advanced clinical practices, particularly in the U.S., where awareness campaigns and screening programs are widespread.
According to the American Heart Association, cardiovascular disease remained the leading cause of death in the U.S. in 2020, accounting for over 928,000 deaths. The economic impact is equally significant, with total CVD costs reaching USD407.3 million between 2018 and 2019, underscoring the need for effective vascular repair solutions such as patches.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 443.6 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 7.9% | 2032 Value Projection: | USD 755.3 Mn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
B. Braun Melsungen AG, C. R. Bard, Inc., LeMaitre Vascular, Inc., Getinge AB, W. L. Gore & Associates, Inc., Edwards Lifesciences Corporation, Baxter International Inc., CryoLife, Inc., Medtronic, and Admedus |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
The increasing prevalence of cardiovascular diseases globally is expected to propel market growth over the forecast period. For instance, according to the data published by the World Health Organization on May 15, 2023, every year, about 805,000 people in the U.S. have a heart attack.
Increasing the older population globally and increasing the chances of a chronic disease like cardiovascular disease is expected to propel market growth over the forecast period. For instance, according to the data published by the World Health Organization in October 2022, in 2050, 80% of older people will be living in low- and middle-income countries. Moreover, in 2020, the number of people aged 60 years and older outnumbered children younger than 5 years.
Key players are launching novel products in the market, which is expected to propel market growth over the forecast period. For instance, on June 30, 2021, Axio Biosolutions, a wound care company, announced U.S. Food and Drug Administration (FDA) clearance of its hemostatic product, Axiostat Patch, which helps control moderate to severe bleeding in vascular procedures, surgical debridement sites, puncture sites, and more.
Increasing research and development activities by market players is expected to aid in market growth over the forecast period. For instance, in September 22, 2021, Terumo Aortic, a medical device company, announced the launch of the co-global surgical graft study known as PANTHER. The study is a prospective and retrospective, multicenter, multi-arm, postmarket study of the company’s range of knitted and woven surgical grafts and cardiovascular patches.
*Definition: Vascular patch is made of polyester-urethane and has been shown to have long-term mechanical stability as well as great biocompatibility.
Share
Share
About Author
Komal Dighe is a Management Consultant with over 8 years of experience in market research and consulting. She excels in managing and delivering high-quality insights and solutions in Health-tech Consulting reports. Her expertise encompasses conducting both primary and secondary research, effectively addressing client requirements, and excelling in market estimation and forecast. Her comprehensive approach ensures that clients receive thorough and accurate analyses, enabling them to make informed decisions and capitalize on market opportunities.
Missing comfort of reading report in your local language? Find your preferred language :
Transform your Strategy with Exclusive Trending Reports :
Frequently Asked Questions
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
Schedule a meeting with report Author
